Hematology and Oncology | Clinical Trials

General Inquiries: 314-454-6018

Cancer Predisposition Todd Druley, MD, PhD druley_t@wustl.edu
Hematological Malignancy (Leukemia & Lymphoma) Jeffrey Magee MD, PhD mageej@wustl.edu
  Laura Schuettpelz MD, PhD schuettpelz_l@wustl.edu
Hemostasis and Thrombosis (Clotting/Bleeding Disorders) David Wilson, MD, PhD wilson_d@wustl.edu
Immune Disorders Jeffrey Bednarski, MD, PhD bednarski_j@wustl.edu
Neuro-Oncology (Brain Tumors) Karen Gauvain, MD gauvaink@wustl.edu
Sickle Cell Disease Monica Hulbert, MD monicahulbert@wustl.edu
Solid Tumors Frederick Huang, MD huang_f@wustl.edu
  Alok Kothari, MD alok@wustl.edu
Stem Cell Transplantation and Cellular Therapy Shalini Shenoy, MD shalinishenoy@wustl.edu
  Sima Bhatt, MD bhatts@wustl.edu
Survivorship Robert Hayashi, MD hayashi_r@wustl.edu


All Cancers

Brain Tumors

Principal Investigator Title
Allison King, MD, PhD Computer Training Program for Younger Patients with a Brain Tumor Who Underwent Radiation Therapy
Robert Hayashi, MD Selinexor in Treating Younger Patients with Recurrent or Refractory Solid Tumors or High Grade Glioma
Karen Gauvain, MD Study of RXDX-101 in Children with Recurrent of Refractory Solid Tumors and Primary CNS Tumors, with or without TRK, ROS1, or ALK Fusions
Karen Gauvain, MD Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors
Joshua Rubin, MD, PhD A Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults with Previously Untreated Low Grade Glioma
Karen Gauvain, MD Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG and LGG
Joshua Rubin, MD, PhD Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma
Karen Gauvain, MD Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma
Karen Gauvain, MD CA209-908 - Phase Ib/II Clinical Trial of Nivolumab Monotherapy and Nivolumab in Combination with Ipilimumab in Pediatric Subjects with High Grade Primary CNS Malignancies
Karen Gauvain, MD PNOC 001 - Phase II Study of Everolimus for Recurrent or Progressive Low-Grade Gliomas in Children
Karen Gauvain, MD H3.3K27M Peptide Vaccine for Children With Newly Diagnosed DIPG and Other Gliomas
Karen Gauvain, MD PNOC013 - A Safety and Pharmacokinetic Study of Single Agent REGN2810 in Pediatric Patients with Relapsed or Refractory Solid or Central Nervous System (CNS) Tumors and a Safety and Efficacy Trial of REGN2810 in Combination with Radiotherapy in Pediatric Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Newly Diagnosed High-Grade Glioma, or Recurrent High-Grade Glioma
Karen Gauvain, MD Phase I-II Study of MEK162 for Children with Ras/Raf Pathway Activated Tumors
Karen Gauvain, MD Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT
Karen Gauvain, MD Vemurafenib in Children With Recurrent/Refractory BRAFV600E-mutant Gliomas
Joshua Rubin, MD, PhD Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt Positive Medulloblastoma
Joshua Rubin, MD, PhD Cognitive Biomarkers in Pediatric Brain Tumor Patients
Robert Hayashi, MD Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
Robert Hayashi, MD Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Robert Hayashi, MD PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Robert Hayashi, MD Selumetinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Robert Hayashi, MD Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Robert Hayashi, MD Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Robert Hayashi, MD Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Robert Hayashi, MD Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

Cancer Predisposition

Principal Investigator Title
Robert Hayashi, MD Phenotypic Characterizations of Cancer Predisposition Syndromes

Hematologic Malignancies (Leukemias & Lymphomas)

Principal Investigator Title
Robert Hayashi, MD Assessing Compliance with Mercaptopurine Treatment in Younger Patients with Acute Lymphoblastic Leukemia in First Remission
Robert Hayashi, MD Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients with Down Syndrome
Robert Hayashi, MD Trentinoin and Arsenic Trioxide in Treating Patients with Untreated Acute Promyelocytic Leukemia
Robert Hayashi, MD A Phase II Study of Ruxolitinib with Chemotherapy in Children with Acute Lymphoblastic Leukemia
Robert Hayashi, MD Blinatumomab in Treating Younger Patients with Relapsed B-Cell Acute Lymphoblastic Leukemia
Robert Hayashi, MD Combination Chemotherapy in Treating Young Patients with Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
Shalini Shenoy, MD Azacitidine and Combination Chemotherapy in Treating Infants with Acute Lymphoblastic Leukemia and KMT2a Gene Rearrangement
Robert Hayashi, MD PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Robert Hayashi, MD A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
Robert Hayashi, MD Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Robert Hayashi, MD Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
Robert Hayashi, MD A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment
Robert Hayashi, MD Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB or Stage IIIB-IVB Hodgkin Lymphoma
Robert Hayashi, MD A Study of Pembrolizumab (MK-3475) in Pediatric Participants with an Advanced Solid Tumor or Lymphoma
Robert Hayashi, MD PI3K/mTOR Inhibitor LY3023414 in Treating Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders with TSC or PI3k/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Robert Hayashi, MD Post Transplant Lymphoproliferative Disease: Analysis of Outcome to Chemotherapy Treatment
Robert Hayashi, MD Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients with EBV-Positive Cluster of Differentiation (CD) 20-Positive Post-Transplant Lymphoproliferative Disorder
Shalini Shenoy, MD A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma

Sickle Cell Disease

Solid Tumors

Principal Investigator Title
Frederick Huang, MD Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma
Robert Hayashi, MD Selinexor in Treating Younger Patients with Recurrent or Refractory Solid Tumors or High Grade Gliomas
Karen Gauvain, MD Study of RXDX-101 in Children with Recurrent of Refractory Solid Tumors and Primary CNS Tumors, with or without TRK, ROS1, or ALK Fusions
Robert Hayashi, MD PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Robert Hayashi, MD A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
Frederick Huang, MD Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
Frederick Huang, MD Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
Robert Hayashi, MD Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Robert Hayashi, MD Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
Robert Hayashi, MD Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Frederick Huang, MD Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Todd Druley, MD, PhD International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry
Alok Kothari, MD Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan
Alok Kothari, MD Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors
Robert Hayashi, MD Nivolumab with or without Ipilimumab in Treating Younger Patients with Recurrent or Refractory Solid Tumors or Sarcomas
Robert Hayashi, MD WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients with Relapsed or Refractory Solid Tumors
Robert Hayashi, MD A Study of Pembrolizumab (MK-3475) in Pediatric Participants with an Advanced Solid Tumor or Lymphoma
Robert Hayashi, MD PI3K/mTOR Inhibitor LY3023414 in Treating Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders with TSC or PI3k/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Robert Hayashi, MD ADVL1614 - A Phase 1/2 Study of VX15/2503 (IND# 136181) in Children, Adolescents or Young Adults with Recurrent or Relapsed Solid Tumors
Robert Hayashi, MD Prexasertib in Treating Pediatric Patients with Recurrent or Refractory Solid Tumors
Robert Hayashi, MD Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients with Recurrent or Refractory Solid Tumors
Robert Hayashi, MD A Study of Ramucirumab (LY3009806) in Children with Refractory Solid Tumors
Robert Hayashi, MD Pevonedistat, Irinotecan Hydrochloride, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Robert Hayashi, MD Entinostat in Treating Pediatric Patients with Recurrent or Refractory Solid Tumors
Robert Hayashi, MD Accelerated v’s Standard BEP Chemotherapy for Patients with Intermediate and Poor-risk Metastatic Germ Cell Tumours
Robert Hayashi, MD Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients with Germ Cell Tumors
Robert Hayashi, MD Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors
Robert Hayashi, MD Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
Robert Hayashi, MD Study of Kidney Tumors in Younger Patients
Robert Hayashi, MD Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours (P3BEP)

Survivorship

Principal Investigator Title
Robert Hayashi, MD Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
Joshua Rubin, MD, PhD Neuropsychological and Behavioral Testing in Younger Patients With Cancer
Robert Hayashi, MD Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors
Robert Hayashi, MD Prevalence of Ototoxicity following Bone Marrow Transplantation and Stem Cell Transplantation in Pediatrics
Robert Hayashi, MD Childhood Cancer Survivor Study (CCSS) - Expansion
Robert Hayashi, MD Knowledge and perceptions of infertility in adolescent female cancer survivors and parents
Robert Hayashi, MD Late Onset and Asymmetric Sensorineural Hearing Loss in Pediatric Cancer Survivors Following Treatment with Cisplatin Containing Chemotherapy Regimens
Caroline Mohrmann, PNP Patient, Family, and Provider Decision-Making in the Setting of Chemotherapy-Induced Hearing Loss
Robert Hayashi, MD Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma
Miranda Camet Retrospective Review of Audiologic Test Results for Pediatric Patients with Beckwith-Wiedemann Syndrome and hemihypertrophy
Shalini Shenoy, MD A Multi-center Retrospective Registry of Children with Sickle Cell Disease following Hematopoietic Cell Transplantation: a Sickle Transplant Alliance for Research (STAR) Project

Transplant & Cellular Therapy

Principal Investigator Title
Shalini Shenoy, MD Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (STRIDE2) (BMT CTN 1503)
Shalini Shenoy, MD Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Jeffrey Bednarski, MD, PhD Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant
Shalini Shenoy, MD Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
Shalini Shenoy, MD UVADEX® and ECP for the Treatment of Pediatric Patients With Steroid Refractory Acute Graft Versus Host Disease
Shalini Shenoy, MD An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
Robert Hayashi, MD Prevalence of Ototoxicity following Bone Marrow Transplantation and Stem Cell Transplantation in Pediatrics
Andrew Cluster, MD Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors (LASCR)
Shalini Shenoy, MD Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMT CTN 1507)
Shalini Shenoy, MD Optimizing Cord Blood and Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502) (CHAMP)
Sima Bhatt, MD CAR-T Cell Therapy for Acute Pre-B Leukemia and Lymphoma
Jeffrey Bednarski, MD, PhD Reduced Intensity Transplant for Immune Deficiency Disorders (Immune Disorder HSCT Protocol)
Robert Hayashi, MD Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

© 2018 by Washington University in St. Louis
One Brookings Drive, St. Louis, MO 63130